Journal: Frontiers in Immunology

Article Title: Development and in vivo evaluation of novel humanized CD19 CAR-T cells for advanced B cell malignancies

doi: 10.3389/fimmu.2026.1798748

Figure Lengend Snippet: Design and characterization of humanized and harmonized anti-CD19 scFvs. (A) Sequence identity analysis comparing the FMC63 VH domain against the two most closely related human VH germlines (H1 and H2) utilized for humanization and harmonization. Schematic representation of the H1 (harmonized) and H2 (humanized) scFv constructs in a VL-linker-VH orientation. Both constructs utilize an identical humanized VL domain . (B) In silico prediction of aggregation propensity for FMC63, humanized and harmonized versions of H1 and humanized H2. (C) Prediction of HLA epitopes within scFvs sequences. Bar plots represent the number of predicted HLA-presented peptides for each unique or shared set among FMC63, H1, and H2, as indicated by the intersection matrix below. Filled dots denote the groups included in each intersection (D) Equilibrium dissociation constant (K D ) of soluble FvFc fusion proteins (scFvs fused to a human IgG1 Fc region) as measured by biolayer interferometry (BLI). (E) Flow cytometric analysis of CD19+ Raji cells stained with the soluble FvFc molecules comparing antigen-binding properties.

Article Snippet: Molecular dynamics simulations were performed using homology models of FMC63 scFv (scFv FMC63 ) and its humanized variants (H1 and H2) named scFv H1 and scFv H2 , constructed based on the FMC63–CD19 crystal structure (PDB ID: 7URV).

Techniques: Sequencing, Construct, In Silico, Staining, Binding Assay

Journal: Frontiers in Immunology

Article Title: Development and in vivo evaluation of novel humanized CD19 CAR-T cells for advanced B cell malignancies

doi: 10.3389/fimmu.2026.1798748

Figure Lengend Snippet: New anti-CD19 CAR-T cells maintain sustained cytotoxic activity during prolonged in vitro challenge. (A) Kinetic killing assays using GFP + Nalm-6 target cells expressing either wild-type CD19 [CD19 WT , (B) or reduced CD19 levels (CD19 Low , (C) ]. The count of residual GFP + cells was quantified every 24 hours throughout a 96-hour co-culture period. Effector-to-target (E:T) ratios were assessed at 1:1, 0.5:1, 0.25:1, and 0.1:1. CAR+ cells (FMC63- black, H1- red and H2- blue). killing activity was compared to that exhibited by Mock-transduced negative control (grey). Cumulative cytotoxicity was compared using Area Under the Curve (AUC) analysis derived from the 96-hour killing kinetics. Assays were performed in triplicate and data are presented as mean ± SD. Statistical significance was determined via Two-Way ANOVA (*p < 0.05; **p < 0.01; ***p < 0.001).

Article Snippet: Molecular dynamics simulations were performed using homology models of FMC63 scFv (scFv FMC63 ) and its humanized variants (H1 and H2) named scFv H1 and scFv H2 , constructed based on the FMC63–CD19 crystal structure (PDB ID: 7URV).

Techniques: Activity Assay, In Vitro, Expressing, Co-Culture Assay, Negative Control, Derivative Assay

Journal: Frontiers in Immunology

Article Title: Development and in vivo evaluation of novel humanized CD19 CAR-T cells for advanced B cell malignancies

doi: 10.3389/fimmu.2026.1798748

Figure Lengend Snippet: Comparative in vivo efficacy of CAR-T variants in a standard tumor burden xenograft model. (A) Schematic representation of the xenograft model used to evaluate CAR T-cell activity in vivo . NSG mice were inoculated with 1 × 10 5 Nalm-6 CD19 WT cells. Two days after tumor inoculation, mice received a single intravenous dose of CAR-T cells (7 × 10 5 ). Tumor burden was monitored by bioluminescence imaging using the IVIS Spectrum in vivo imaging system every 7 days. Mice were euthanized according to predefined clinical criteria, and survival was recorded. (B) Kaplan-Meier survival curves and statistical analysis of the advanced disease model. Experimental groups are indicated: Control Tumor Only (untreated mice, PBS-inoculated; brown) and CAR-T cells treated- FMC63 CAR-T (black), H1 CAR-T (red), and H2 CAR-T (blue). (C) Longitudinal assessment of tumor burden quantified by bioluminescence intensity (Total Flux, photons/second). (D) Kinetics of tumor progression and regression monitored by representative bioluminescence imaging across all experimental cohorts. End points were determined by ethical criteria for euthanasia.

Article Snippet: Molecular dynamics simulations were performed using homology models of FMC63 scFv (scFv FMC63 ) and its humanized variants (H1 and H2) named scFv H1 and scFv H2 , constructed based on the FMC63–CD19 crystal structure (PDB ID: 7URV).

Techniques: In Vivo, Activity Assay, Imaging, In Vivo Imaging, Control

Journal: Frontiers in Immunology

Article Title: Development and in vivo evaluation of novel humanized CD19 CAR-T cells for advanced B cell malignancies

doi: 10.3389/fimmu.2026.1798748

Figure Lengend Snippet: Antitumor activity of engineered CAR-T cells against established, advanced-stage tumors. (A) Schematic of the xenograft model used to evaluate CAR T-cell activity in vivo . NSG mice were inoculated with 1 × 10 5 Nalm-6 CD19 Low cells. Eleven days after tumor inoculation, mice received a single intravenous dose of CAR T cells (1 × 10 6 ). Tumor burden was monitored by bioluminescence imaging using the IVIS Spectrum in vivo imaging system every 7 days. Mice were euthanized according to predefined clinical criteria, and survival was recorded. (B) Kaplan-Meier survival curves and statistical analysis of the advanced disease model. Experimental groups are indicated as follows: vehicle control (brown), Mock (electroporated, non-transfected cells; gray), FMC63 CAR-T (black), H1 CAR-T (red), and H2 CAR-T (blue). (C) Longitudinal assessment of tumor burden and anatomical localization, quantified by bioluminescence intensity (Total Flux, photons/second). (D) Kinetics of tumor progression and regression monitored by representative bioluminescence imaging across all experimental cohorts.

Article Snippet: Molecular dynamics simulations were performed using homology models of FMC63 scFv (scFv FMC63 ) and its humanized variants (H1 and H2) named scFv H1 and scFv H2 , constructed based on the FMC63–CD19 crystal structure (PDB ID: 7URV).

Techniques: Activity Assay, In Vivo, Imaging, In Vivo Imaging, Control, Transfection

Journal: bioRxiv

Article Title: Cysteine-Engineered CAR-T Cells to Counter Antigen Escape in B Cell Lymphoma

doi: 10.1101/2025.04.01.646520

Figure Lengend Snippet: a , Location of the mutated residues N92, D156, S190, G228, and S229 within the three-dimensional structure of FMC63 in complex with CD19 (data retrieved from PDB entry ID 7URV). b , Schematic representation of the individual mutated residues within the linear sequence of FMC63. LC – light chain, HC – heavy chain. c,d , Luciferase-based cytotoxicity assays of CD19-CAR-T cells co-cultured with JeKo-1 lymphoma or JeKo-1 CD19-knockout at different E:T ratios for 48 hours. Tested constructs are non-transduced (●), WT CD19-CAR (▪), N92C CD19-CAR (○), D156C CD19-CAR (▴), S190/ C CD19-CAR (♦), G228C CD19-CAR (⬣), and S229C CD19-CAR (▾). Mean values ± SEM of n=3 ( c ) or N=3, n=3 ( d ) replicates are shown. Significance of differences was assessed via 2-way ANOVA followed by Tukey’s post-hoc test (n.s. – not significant; * – p<0.05; ** – p<0.01; *** – p<0.001). All indicated significance levels are in comparison to WT CD19-CAR-T cells.

Article Snippet: Briefly, all nanobody-based CAR-T cells were incubated with MonoRab™ Rabbit Anti-Camelid VHH Cocktail iFluor 647 (1:500; GenScript, Piscataway, NJ) and CD19-CAR-T cells were incubated with Recombinant Human CD19 Fc Chimera Alexa Fluor® 647 (1:500; Bio-Techne, Minneapolis, MN) and/or anti-idiotypic FMC63 scFv Mouse antibody, FITC conjugate (1:50; ACROBiosystems, Newark, DE) for FMC63 mutants at room temperature (RT) for 30 min.

Techniques: Sequencing, Luciferase, Cell Culture, Knock-Out, Construct, Comparison